Skip to main content

Table 2 Disease activity according to treatment

From: Maintained activity in ankylosing spondylitis patients treated with TNFi and/or NSAID for at least 12 weeks: a cross-sectional study in Brazil

 

All patients

(n = 378)

Using only NSAID

(n = 42)

Using only TNFi

(n = 281)

Using both TNFi and NSAID

(n = 55)

P-value

BASDAI score - n (%)

    

< 0.01*

 Inactive disease (< 2)

103 (27.25)

2 (4.76)

97 (34.52)

4 (7.27)

 

 Low activity/suboptimal control (≥ 2 and < 4)

90 (23.81)

9 (21.43)

75 (26.69)

6 (10.91)

 

 Active disease (≥ 4)

185 (48.94)

31 (73.81)

109 (38.79)

45 (81.82)

 

BASDAI mean (SD)

4.06 (2.67)

6.07 (2.50) b

3.43 (2.50) a

5.77 (2.09) b

< 0.01**

ASDAS-CRP score - n (%)

    

< 0.01*

 Inactive disease (< 1.3)

36 (26.28)

1 (5.26)

33 (34.38)

2 (9.09)

 

 Low activity/suboptimal control (≥ 1.3 - <2.1)

31 (22.63)

2 (10.53)

28 (29.17)

1 (4.55)

 

 High activity (≥ 2.1 - <3.5)

49 (35.77)

11 (57.89)

25 (26.04)

13 (59.09)

 

 Very high activity (≥ 3.5)

21 (15.33)

5 (26.32)

10 (10.42)

6 (27.27)

 

ASDAS-CRP mean (SD)

2.28 (1.18)

3.01 (0.90) b

1.96 (1.07) a

3.07 (1.24) b

< 0.01**

  1. AS ankylosing spondylitis, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, NSAID nonsteroidal anti-inflammatory drug, SD standard deviation, TNFi tumor necrosis factor inhibitors